MSCCOP

		home :: clinical trials :: treatment trials :: clinical trials

		CLINICAL TRIALS

AVAILABLE CLINICAL TRIALS

Respiratory Clinical Trials
	Ref #	Title
NSCLC Stage III/IV	LUN 196	Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs Pemetrexed/Carboplatin/Bevacizumab in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
NSCLC	CALGB 30506	A Randomized Phase III Trial to Evaluate the Potential Utility of a Genomic Prognostic Model to Identify Stage I NSCLC Patients as Candidates for Adjuvant Chemotherapy
NSCLC	SWOG S0819	“A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)."
Limited SCLC	CALGB 30610/RTOG 0538	Phase III Randomized Study of Three Different Thoracic Radiotherapy Regimens in Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
NSCLC	RTOG 0813	SEAMLESS PHASE I/II STUDY OF STEREOTACTIC LUNG RADIOTHERAPY (SBRT) FOR EARLY STAGE, CENTRALLY LOCATED,NON-SMALL CELL LUNG CANCER (NSCLC) IN MEDICALLY INOPERABLE PATIENTS
Small Cell Lung Cancer	CALGB 30504	COMBINATION CISPLATIN, ETOPOSIDE AND SUNITINIB MALATE FOR UNTREATED EXTENSIVE STAGE SMALL CELL LUNG CANCER: A PHASE I/II STUDY
NSCLC	RTOG 0617	A Randomized Phase III Comparison of Standard- Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer
NSCLC, 2nd Line	CALGB 30704	A RANDOMIZED PHASE II STUDY TO ASSESS THE EFFICACY OF PEMETREXED OR SUNITINIB OR PEMETREXED PLUS SUNITINIB IN THE SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
NSCLC PS=2	Alimta	PHASE III TRIAL OF SINGLE-AGENT PEMETREXED (ALIMTA®) VERSUS THE COMBINATION OF CARBOPLATIN AND PEMETREXED IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER AND PERFORMANCE STATUS OF 2
NSCLC	CALGB 30605	A PHASE II STUDY OF INDUCTION CHEMOTHERAPY FOLLOWED BY THORACIC RADIOTHERAPY AND ERLOTINIB IN POOR-RISK STAGE III NON-SMALL CELL LUNG CANCER
Stage IB- lllA NSCLC	CTSU E1505	This study evaluates the effectiveness of post-surgical chemotherapy compared to chemotherapy plus the monoclonal antibody drug Avastin (bevacizumab), which targets blood vessels that feed tumors. Patients are randomized into two groups, one of which receives only chemotherapy while the other group receives Avastin in combination with chemotherapy. Patients with stage IB, stage II, or stage IIIA non-small cell lung cancer (NSCLC) that was surgically removed are eligible.
Epidemiology Study Stage I - IIIB	CTSU S0424	This study collects tissue and blood specimens from patients with non-small cell lung cancer (NSCLC) and has patients fill out a questionnaire. The study’s objective is to learn more about the disease, specifically why more women than men are diagnosed with certain types of lung cancer and if there are risk factors other than smoking that contribute to women’s higher risk for lung cancer. To be eligible, patients must be newly diagnosed with stage I, II, IIIA, or IIIB NSCLC. Patients participate once annually for five years.